Author:
Roger Claire,Roberts Jason A.,Muller Laurent
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference164 articles.
1. Johnson AP, Warner M, Livermore DM. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom. J Antimicrob Chemother. 2000;45(2):225–30.
2. Full prescribing information: Sivextro®. 2015.
http://sivextro.com/pdf/sivextro-prescribing-info.pdf
. Accessed 7 May 2017.
3. European public assessment report summary for the public: Sivextro®. 2015.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002846/WC500184804.pdf
. Accessed 7 May 2017.
4. Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998–2000. Diagn Microbiol Infect Dis. 2002;43(1):65–73.
5. Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother. 1998;42(3):721–4.
Cited by
97 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献